Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. Its product portfolio includes heart valves, stent grafts, surgical sealants, and vascular grafts, marketed primarily to physicians and hospitals through a direct sales team. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Incorporated in 1984, it is headquartered in Kennesaw, Georgia.
Artivion Q2 revenue rises 9% on heart valve and stent graft growth
Artivion reported second-quarter 2026 revenue of $125.8 million, up 9% on a constant currency basis, driven by growth in heart valve and stent graft products. Adjusted EBITDA rose 7% to $26.4 million, while adjusted EBITDA margin declined 90 basis points to 21% due to increased R&D investment and the Endospan acquisition. Stent graft revenue grew 12% to $46.4 million, On-X valve revenue increased 18% to $30.5 million, preservation services revenue rose 1% to $25.9 million, and surgical sealant revenue fell 2% to $19.3 million. The company received U.S. FDA premarket approval for its AMDS hybrid prosthesis in late June and completed the acquisition of Endospan during the quarter, adding the NEXUS Aortic Arch Stent Graft System. Full-year revenue guidance was reiterated at $480 million to $496 million, representing adjusted constant currency growth of 7% to 11%, and full-year adjusted EBITDA guidance was reiterated at $92 million to $99 million.
Conestoga Capital Says Artivion's Stent Graft Sales Missed, but Sees Long-Term Growth
Conestoga Capital Advisors reported that Artivion, Inc. detracted from portfolio performance in the second quarter of 2026 after first-quarter stent graft sales fell short of expectations, citing slower-than-anticipated AMDS product adoption and softer international demand. The firm noted that reorder activity remains strong and expects adoption to accelerate as additional hospitals complete the approval process, maintaining that Artivion's expanding aortic portfolio and product pipeline provide meaningful long-term growth opportunities. Artivion shares closed at $26.55 on August 6, 2026, with a market capitalization of $1.29 billion, and have lost 32.45% over the past 52 weeks.
Artivion Shares Detract After AMDS Sales Miss Hurts Outlook
Artivion shares detracted from performance in the second quarter after the company modestly lowered its full-year outlook, primarily due to slower-than-expected starter set sales for AMDS, its key new product cycle. The medical device maker reported in-line first-quarter results but the guidance cut weighed on the stock, according to the Alger Weatherbie Specialized Growth Fund's Q2 2026 investor letter. Artivion closed at $25.37 per share on July 20, 2026, with a one-month return of 22.68% and a 52-week loss of 16.55%, giving it a market capitalization of $1.23 billion. The fund noted that the Industrials and Information Technology sectors contributed to relative performance, while Financials and Consumer Discretionary detracted.
StockStory names Workiva and Nextpower as growth stocks to watch, flags Artivion as one to sell
StockStory highlights Workiva and Nextpower as growth stocks poised to flourish, while cautioning against Artivion. Workiva, a cloud-based financial reporting platform, saw annual recurring revenue grow 22.1% and boasts a 79.4% gross margin. Nextpower, a solar tracker provider, achieved 19.3% annual revenue growth over two years and significantly improved its free cash flow margin. In contrast, Artivion faces challenges including a small revenue base of $458.7 million, negative free cash flow margin, and low returns on capital. Workiva trades at 2.6 times forward price-to-sales, Nextpower at 25.6 times forward price-to-earnings, and Artivion at 44.2 times forward price-to-earnings.
Artivion Secures FDA Approval for AMDS Hybrid Prosthesis Device
Artivion has received FDA premarket approval for its AMDS Hybrid Prosthesis to treat acute DeBakey Type I aortic dissections with malperfusion. The approval removes the institutional review board requirement tied to the device's previous Humanitarian Device Exemption, enabling broader U.S. hospital adoption and allowing the company to pursue an estimated $150 million annual market opportunity. The device is the world's first aortic arch remodeling device for this condition and was supported by the PERSEVERE trial, which showed a 72% reduction in all-cause mortality and zero distal anastomotic new entry tears at 30 days. Artivion estimates that approximately 6,000 U.S. patients experience such dissections each year, with the approved indication covering roughly 60% of those cases. The company's shares have traded flat since the announcement, though they are down 50.7% year-to-date.
Artivion Wins FDA Approval For AMDS Hybrid Prosthesis
Artivion has received U.S. FDA premarket approval for its AMDS Hybrid Prosthesis, the world's first aortic arch remodeling device for treating acute DeBakey Type I aortic dissections. The approval was supported by the PERSEVERE U.S. IDE trial, which demonstrated a 72% reduction in all-cause mortality and a 54% reduction in primary major adverse events at 30 days compared to the standard hemiarch procedure, with zero distal anastomotic new entry tears. AMDS was previously available under a Humanitarian Device Exemption. The company stated that the PMA approval positions it to fully address an estimated $150 million annual U.S. market opportunity. Artivion shares rose more than 2% in pre-market trading after closing at $23.61 on Friday.
StockStory highlights three profitable companies it avoids despite their current earnings: Tesla, Artivion, and Mettler-Toledo. Tesla trades at 174.4 times forward price-to-earnings with a trailing 12-month GAAP operating margin of 5%, facing cyclical auto demand and execution concerns. Artivion, with a $458.7 million revenue base and 8.2% operating margin, is seen as subscale and lacking free cash flow, trading at 43.3 times forward earnings. Mettler-Toledo posts a 27.5% operating margin but shows slowing organic growth and declining returns on capital, priced at 25.1 times forward earnings.
Merit Medical Systems Q1 revenue beats estimates, raises full-year guidance
Merit Medical Systems reported first-quarter revenues of $381.9 million, up 7.5% year on year and exceeding analyst expectations by 1.2%. The company also beat earnings per share estimates and raised its full-year guidance, the highest raise among the four medical devices and supplies stocks tracked in the cardiology, neurology, and vascular segment. ICU Medical posted revenues of $525.8 million, down 12.3% year on year but still beating estimates by 1.2%, while Artivion's revenues grew 17.5% to $116.3 million but missed earnings estimates and provided weak guidance, sending its stock down 38.1%. Penumbra's revenues rose 15.6% to $374.8 million, topping estimates by 0.7%, though it missed earnings per share forecasts. Overall, the group's revenues beat consensus estimates by 0.9% on average, but share prices have fallen 6.2% since reporting.
United States